218 related articles for article (PubMed ID: 36870294)
1. Addressing Modern Diagnostic Pathology for Patient-Derived Soft Tissue Sarcosphere Models in the Era of Functional Precision Oncology.
Chen Y; Herzog M; Pliego-Mendieta A; Bühler MM; Harnisch KJ; Haberecker M; Arnold F; Planas-Paz L; Pauli C
Lab Invest; 2023 Apr; 103(4):100039. PubMed ID: 36870294
[TBL] [Abstract][Full Text] [Related]
2. Integration of genomic copy number variations and chemotherapy-response biomarkers in pediatric sarcoma.
Cheng L; Pandya PH; Liu E; Chandra P; Wang L; Murray ME; Carter J; Ferguson M; Saadatzadeh MR; Bijangi-Visheshsaraei K; Marshall M; Li L; Pollok KE; Renbarger JL
BMC Med Genomics; 2019 Jan; 12(Suppl 1):23. PubMed ID: 30704460
[TBL] [Abstract][Full Text] [Related]
3. Assessment of Predictive Biomarkers of the Response to Pazopanib Based on an Integrative Analysis of High-grade Soft-tissue Sarcomas: Analysis of a Tumor Sample from a Responder and Patients with Other Soft-tissue Sarcomas.
Suehara Y; Kohsaka S; Yamaguchi S; Hayashi T; Kurihara T; Sano K; Sasa K; Akaike K; Ueno T; Kojima S; Ikegami M; Mizuno S; Okubo T; Kim Y; Kaneko K; Saito T; Kato S; Mano H
Clin Orthop Relat Res; 2020 Nov; 478(11):2461-2476. PubMed ID: 32567826
[TBL] [Abstract][Full Text] [Related]
4. Establishment, characterization and functional testing of two novel ex vivo extraskeletal myxoid chondrosarcoma (EMC) cell models.
Bangerter JL; Harnisch KJ; Chen Y; Hagedorn C; Planas-Paz L; Pauli C
Hum Cell; 2023 Jan; 36(1):446-455. PubMed ID: 36316541
[TBL] [Abstract][Full Text] [Related]
5. The 2020 WHO Classification of Soft Tissue Tumours: news and perspectives.
Sbaraglia M; Bellan E; Dei Tos AP
Pathologica; 2021 Apr; 113(2):70-84. PubMed ID: 33179614
[TBL] [Abstract][Full Text] [Related]
6. A precision medicine approach in sarcoma: identification of patients who may benefit from early use of pazopanib.
Alavi SN; Florou V; Tinoco G; Trent JC; Wilky BA
Discov Med; 2018 Mar; 25(137):131-144. PubMed ID: 29641974
[TBL] [Abstract][Full Text] [Related]
7. The Role of Next-Generation Sequencing in Sarcomas: Evolution From Light Microscope to Molecular Microscope.
Groisberg R; Roszik J; Conley A; Patel SR; Subbiah V
Curr Oncol Rep; 2017 Oct; 19(12):78. PubMed ID: 29030741
[TBL] [Abstract][Full Text] [Related]
8. Sarcoma treatment in the era of molecular medicine.
Grünewald TG; Alonso M; Avnet S; Banito A; Burdach S; Cidre-Aranaz F; Di Pompo G; Distel M; Dorado-Garcia H; Garcia-Castro J; González-González L; Grigoriadis AE; Kasan M; Koelsche C; Krumbholz M; Lecanda F; Lemma S; Longo DL; Madrigal-Esquivel C; Morales-Molina Á; Musa J; Ohmura S; Ory B; Pereira-Silva M; Perut F; Rodriguez R; Seeling C; Al Shaaili N; Shaabani S; Shiavone K; Sinha S; Tomazou EM; Trautmann M; Vela M; Versleijen-Jonkers YM; Visgauss J; Zalacain M; Schober SJ; Lissat A; English WR; Baldini N; Heymann D
EMBO Mol Med; 2020 Nov; 12(11):e11131. PubMed ID: 33047515
[TBL] [Abstract][Full Text] [Related]
9. Molecular Pathogenesis and Diagnostic, Prognostic and Predictive Molecular Markers in Sarcoma.
Mariño-Enríquez A; Bovée JV
Surg Pathol Clin; 2016 Sep; 9(3):457-73. PubMed ID: 27523972
[TBL] [Abstract][Full Text] [Related]
10. Current status of biomarker testing in historically rare, high-unmet-need tumors: soft tissue sarcomas and thyroid cancers.
Schroader B; Kong S; Anderson S; Williamson T; Sireci A; Shields K
Expert Rev Anticancer Ther; 2019 Nov; 19(11):929-938. PubMed ID: 31622558
[No Abstract] [Full Text] [Related]
11. New tools for old drugs: Functional genetic screens to optimize current chemotherapy.
Gerhards NM; Rottenberg S
Drug Resist Updat; 2018 Jan; 36():30-46. PubMed ID: 29499836
[TBL] [Abstract][Full Text] [Related]
12. Fluorescence in Situ Hybridization (FISH) for Differential Diagnosis of Soft Tissue Sarcomas.
Asif A; Mushtaq S; Hassan U; Akhtar N; Hussain M; Azam M; Qazi R
Asian Pac J Cancer Prev; 2018 Mar; 19(3):655-660. PubMed ID: 29580035
[TBL] [Abstract][Full Text] [Related]
13. A Functional Precision Oncology Approach to Identify Treatment Strategies for Myxofibrosarcoma Patients.
Pauli C; De Boni L; Pauwels JE; Chen Y; Planas-Paz L; Shaw R; Emerling BM; Grandori C; Hopkins BD; Rubin MA
Mol Cancer Res; 2022 Feb; 20(2):244-252. PubMed ID: 34728552
[TBL] [Abstract][Full Text] [Related]
14. Micrometastatic Drug Screening Platform Shows Heterogeneous Response to MAP Chemotherapy in Osteosarcoma Cell Lines.
Collier CD; Wirtz EC; Knafler GJ; Morris WZ; Getty PJ; Greenfield EM
Clin Orthop Relat Res; 2018 Jul; 476(7):1400-1411. PubMed ID: 29481344
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic classification of soft tissue malignancies: A review and update from a surgical pathology perspective.
Cloutier JM; Charville GW
Curr Probl Cancer; 2019 Aug; 43(4):250-272. PubMed ID: 31200960
[TBL] [Abstract][Full Text] [Related]
16. Novel fusion sarcomas including targetable NTRK and ALK.
Chen T; Wang Y; Goetz L; Corey Z; Dougher MC; Smith JD; Fox EJ; Freiberg AS; Flemming D; Fanburg-Smith JC
Ann Diagn Pathol; 2021 Oct; 54():151800. PubMed ID: 34464935
[TBL] [Abstract][Full Text] [Related]
17. The past, present, and future of cytotoxic chemotherapy and pathway-directed targeted agents for soft tissue sarcoma.
Ryan CW; Desai J
Am Soc Clin Oncol Educ Book; 2013; ():. PubMed ID: 23714556
[TBL] [Abstract][Full Text] [Related]
18. Contemporary Sarcoma Diagnosis, Genetics, and Genomics.
Schaefer IM; Cote GM; Hornick JL
J Clin Oncol; 2018 Jan; 36(2):101-110. PubMed ID: 29220288
[TBL] [Abstract][Full Text] [Related]
19. Soft tissue sarcomas in the precision medicine era: new advances in clinical practice and future perspectives.
Badalamenti G; Messina C; De Luca I; Musso E; Casarin A; Incorvaia L
Radiol Med; 2019 Apr; 124(4):259-265. PubMed ID: 29619613
[TBL] [Abstract][Full Text] [Related]
20. TRK inhibition in soft tissue sarcomas: A comprehensive review.
Assi T; Rassy E; Nassereddine H; Farhat F; Karak FE; Kattan J; Ghosn M
Semin Oncol; 2020 Feb; 47(1):73-84. PubMed ID: 32201016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
